This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.
Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.
Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound.
Presence of pelvic pain (VAS > 4) during the last three months.
No indication for surgical intervention at the time of inclusion in the study.
Patients under 18 years of age.
Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day.
Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.
Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.